An observational study in Neuroendocrine Tumors, NET, sponsored by AHS Cancer Control Alberta. Active, not recruiting at 1 site in Canada. Open to participants aged 14 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by AHS Cancer Control Alberta · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Neuroendocrine Tumors with a site in Canada — 11 open to participants now, 20 under way, 4 of them phase 3. Neuroendocrine Tumors · Canada.
Among the 42 studies in Neuroendocrine Tumors with a site in Canada, this one is one of 3 that started in 2012, is one of 9 observational ones, reaches primary completion later than 14 of the 19 other live ones, and was the 8th registered.
544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →11 of the 42 studies in Neuroendocrine Tumors with a site in Canada are open now. Recruiting first, the newest first:
RayzeBio, Inc. · Sites in Canada, United States
Ages 18+
Exelixis · Sites in Canada, United States, Australia and 15 more countries
Ages 18+
Australasian Gastro-Intestinal Trials Group · Sites in Canada, Australia
Ages 18+
Alberta Health services · Sites in Canada
Ages 18–100
University of Alberta · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 14 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 8 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 115 is below the median of 134 across 130 observational studies indexed under Neuroendocrine Tumors.
Median enrollment 160 across the 33 interventional studies, 115 across the 9 observational. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 42 have an industry lead sponsor. The 10 most frequent:
AHS Cancer Control Alberta is the lead sponsor of 187 studies on the registry; 24 are open to participants now.
AHS Cancer Control Alberta has 3 studies filed under Neuroendocrine Tumors — fewer than ten, so there is no comparison to draw.
8 of the studies in Neuroendocrine Tumors with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477576Phase 3RayzeBio, Inc.Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | 2026-12 |
| NCT05255159University of AlbertaLesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors | 2026-12 |
| NCT05673031Alberta Health services68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors | 2027-01-01 |
| NCT07165132RayzeBio, Inc.Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | 2027-02 |
| NCT04804371University Health Network, TorontoDual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors | 2027-02-22 |
Add all 8 to your calendar (.ics) → With an account.
Among the 42 studies in Neuroendocrine Tumors with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.
Limited to those subjects with neuroendocrine tumors who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.
Subjects with neuroendocrine tumours who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.
The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE
Data (Radioisotope and CT/MRI images, blood assays and Quality of Life Questionnaires, pre and post treatment) will be collected to determine tumor response of subjects with NET after treatment with Lu-177 DOTA-TATE.
Time frame: Retrospective data January 2010 - April 30, 2014
Safety and other relevant information on subjects treated with Lu-177 DOTA-TATE
Safety data will include blood counts and chemistry, GFR and adverse events, pre and post treatment. Other data includes patient demographics.
Time frame: Retrospective data January 2010 - April 30, 2014
Started Aug 2012 (actual). Primary completion is estimated for Dec 2027, 184 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.